Anand Rathi recommends Jubilant Ingrevia as buy with ₹900 target
Business
Anand Rathi is recommending Jubilant Ingrevia as a buy, setting a target price of ₹900.
The call comes after the company's nutrition and chemical segments showed strong growth and better pricing.
Q2 EBITDA jumps 57% to ₹210Cr
Jubilant Ingrevia's Q2 FY2027 numbers were impressive: EBITDA jumped 57% year-on-year to about ₹2.1 billion, beating estimates by 12%.
Margins also improved thanks to higher production of human- and cosmetic-grade B3 and stronger niacinamide prices.
While there's some uncertainty around a big agro contract for next year, analysts still see solid growth ahead and are sticking with their upbeat outlook.